RADNOR, Pa., Jan. 2 /PRNewswire/ -- The following statement was issued today by the law firm of Schiffrin Barroway Topaz & Kessler, LLP:
Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Southern District of New York on behalf of all purchasers of the securities of Sanofi-Aventis (NYSE: SNY) ("Sanofi" or the "Company") from February 17, 2006 through June 13, 2007, inclusive (the "Class Period").
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Schiffrin Barroway Topaz & Kessler, LLP (Darren J. Check, Esq. or Richard A. Maniskas, Esq.) toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at email@example.com.
The Complaint charges Sanofi and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Sanofi is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. More specifically, the Complaint alleges that the Company failed to disclose material adverse data concerning Zimulti's tendency to cause a statistically significant increase in psychiatric problems, including suicidal thoughts and actions.
On June 13, 2007, an Advisory Panel to the Food and Drug Administration
("FDA") unanimously voted that Sanfi had not provided the panel with enough
information on the safety of Zimulti (rimonabant), and unanimously
recommended that the FDA reject Sanofi's Zimulti application. FDA
scientists provided an analysis of 13 studies which showed that 26 percent
of patients taking the recommended dose of Zimulti had psychiatric side
|SOURCE Schiffrin Barroway Topaz & Kessler, LLP|
Copyright©2008 PR Newswire.
All rights reserved